ADMA Biologics publishes data showing optimized IVIG process reduces impurities linked to thrombosis risk.

ADMA Biologics announced a peer-reviewed publication revealing that its optimized intravenous immune globulin (IVIG) manufacturing process effectively removes procoagulant impurities associated with thromboembolic events while maintaining immunoglobulin quality and increasing IgG yield. Analytical tests on commercial lots showed very low procoagulant activity and no thromboembolic events reported during postmarketing surveillance from July 2025 to July 2026. This advancement supports the safety and quality of ADMA's IVIG products, benefiting patients requiring lifelong immune globulin therapy. The company continues to emphasize manufacturing innovation to enhance patient outcomes.

ADMA Biologics shares trade at USD 10.35 on Pluang as of Oct 15, 2026, 17:42 WIB, with a slight 0.10% gain for the day. The stock's market cap stands at $2.32 billion, reflecting steady investor interest despite a 100% sell order activity on the platform. The typical holding period for ADMA on Pluang is 18 days, indicating moderate trading frequency among users.